214 related articles for article (PubMed ID: 28493933)
21. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.
Foy KC; Liu Z; Phillips G; Miller M; Kaumaya PT
J Biol Chem; 2011 Apr; 286(15):13626-37. PubMed ID: 21325276
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino G; Wiechmann L; Osborne CK; Schiff R
Endocr Rev; 2008 Apr; 29(2):217-33. PubMed ID: 18216219
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting HER3 Hyperphosphorylation in HER2-Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells.
Villar-Alvarez E; Golán-Cancela I; Pardo A; Velasco B; Fernández-Vega J; Cambón A; Al-Modlej A; Topete A; Barbosa S; Costoya JA; Taboada P
Small; 2023 Dec; 19(50):e2303934. PubMed ID: 37632323
[TBL] [Abstract][Full Text] [Related]
24. Elacestrant: First Approval.
Hoy SM
Drugs; 2023 Apr; 83(6):555-561. PubMed ID: 37060385
[TBL] [Abstract][Full Text] [Related]
25. Activating HER3 mutations in breast cancer.
Mishra R; Alanazi S; Yuan L; Solomon T; Thaker TM; Jura N; Garrett JT
Oncotarget; 2018 Jun; 9(45):27773-27788. PubMed ID: 29963236
[TBL] [Abstract][Full Text] [Related]
26. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities.
Yan S; Ji J; Zhang Z; Imam M; Chen H; Zhang D; Wang J
Biomed Pharmacother; 2024 Jun; 175():116615. PubMed ID: 38663101
[TBL] [Abstract][Full Text] [Related]
27. Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.
Bahnassy S; Stires H; Jin L; Tam S; Mobin D; Balachandran M; Podar M; McCoy MD; Beckman RA; Riggins RB
bioRxiv; 2023 Aug; ():. PubMed ID: 37662291
[TBL] [Abstract][Full Text] [Related]
28. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER
Lowenfeld L; Zaheer S; Oechsle C; Fracol M; Datta J; Xu S; Fitzpatrick E; Roses RE; Fisher CS; McDonald ES; Zhang PJ; DeMichele A; Mick R; Koski GK; Czerniecki BJ
Oncoimmunology; 2017; 6(9):e1207032. PubMed ID: 28932627
[TBL] [Abstract][Full Text] [Related]
29. Self-inhibition of HER2 and HER3 at fever temperatures may prevent their hetero-dimerization.
Singh PK; Stan RC
J Biomol Struct Dyn; 2024 Jul; 42(10):5470-5473. PubMed ID: 37342980
[TBL] [Abstract][Full Text] [Related]
30. Editorial: Cancer treatment and early detection targeting HER receptors, Volume II.
Cai X; Zhang L; Chen S
Front Mol Biosci; 2023; 10():1229765. PubMed ID: 37426424
[No Abstract] [Full Text] [Related]
31. Correction: Induction of phenotypic changes in HER2-postive breast cancer cells
Frank-Kamenetskii A; Mook J; Reeves M; Boulanger CA; Meyer TJ; Ragle L; Jordan HC; Smith GH; Booth BW
Oncotarget; 2023 Sep; 14():842. PubMed ID: 37769034
[No Abstract] [Full Text] [Related]
32. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
33. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
[No Abstract] [Full Text] [Related]
34. Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Augereau P; Patsouris A; Bourbouloux E; Gourmelon C; Abadie Lacourtoisie S; Berton Rigaud D; Soulié P; Frenel JS; Campone M
Ther Adv Med Oncol; 2017 May; 9(5):335-346. PubMed ID: 28529550
[TBL] [Abstract][Full Text] [Related]
35. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
36. New Approaches to Endocrine Therapy for Breast Cancer.
Gradishar WJ
J Natl Compr Canc Netw; 2017 May; 15(5S):679-681. PubMed ID: 28515242
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab emtansine in HER2-positive metastatic breast cancer.
Montemurro F
Lancet Oncol; 2017 Jun; 18(6):696-697. PubMed ID: 28526537
[No Abstract] [Full Text] [Related]
38. Safety and efficacy evaluation of pertuzumab in patients with solid tumors.
Zhu C; Ling W; Zhang J; Gao H; Shen K; Ma X
Medicine (Baltimore); 2017 May; 96(20):e6870. PubMed ID: 28514302
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
40. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
